ArticleEMBO reports2011
Structural analysis of 5'-mRNA-cap interactions with the human AGO2 MID domain.
Article in EMBO reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Engineered human Argonaute 2 for targeted C-to-U RNA base editing.Nature biotechnology · 2026Article
- Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.Frontiers in pharmacology · 2025Review
- Investigation of Strand-Selective Interaction of SNA-Modified siRNA with AGO2-MID.International journal of molecular sciences · 2020Article
- Mechanistic Insights into MicroRNA-Mediated Gene Silencing.Cold Spring Harbor perspectives in biology · 2019Review
- Differences in silencing of mismatched targets by sliced versus diced siRNAs.Nucleic acids research · 2018Article
- MicroRNAs recruit eIF4E2 to repress translation of target mRNAs.Protein & cell · 2017Article
- A Simple and Cost-Effective Approach for In Vitro Production of Sliced siRNAs as Potent Triggers for RNAi.Molecular therapy. Nucleic acids · 2017Article
- siRNA carrying an (E)-vinylphosphonate moiety at the 5΄ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2.Nucleic acids research · 2017Article
- MicroRNA-mediated target mRNA cleavage and 3'-uridylation in human cells.Scientific reports · 2016Article
- Guidelines for the optimal design of miRNA-based shRNAs.Methods (San Diego, Calif.) · 2016Review
- miRISC recruits decapping factors to miRNA targets to enhance their degradation.Nucleic acids research · 2013Article
- Molecular dissection of human Argonaute proteins by DNA shuffling.Nature structural & molecular biology · 2013Article
- eIF4GI facilitates the MicroRNA-mediated gene silencing.PloS one · 2013Article
- The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC.Nature structural & molecular biology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In RNA silencing, microRNA (miRNA)-mediated translational repression occurs through mechanisms that do not invoke messenger-RNA (mRNA) target cleavage by Argonaute proteins. The nature of these mechanisms is unclear, but several recent studies have proposed that a direct interaction between the mRNA-cap and the middle (MID) domain of Argonautes is involved. Here, we present crystallographic and NMR data demonstrating that cap analogues do not bind significantly to the isolated MID domain of human Argonaute 2 (hAGO2) and are found in the miRNA 5'-nucleotide binding site in an implausible binding mode. Additionally, in vitro pull-down experiments with full-length hAGO2 indicate that the interaction with cap analogues is nonspecific.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.